Progress in the research of immunotherapy‑related hyperprogression (Review).

hyperprogression immune checkpoint inhibitors immune microenvironment macrophage tumor

Journal

Molecular and clinical oncology
ISSN: 2049-9469
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 21 02 2023
accepted: 02 11 2023
medline: 15 1 2024
pubmed: 15 1 2024
entrez: 15 1 2024
Statut: epublish

Résumé

Immunotherapy has become an effective method for the treatment of a variety of malignant tumors. However, with the development of immunotherapy, the phenomenon of hyperprogression in patients with cancer has gradually attracted attention. Hyperprogression refers to a condition in which the progression of a disease during treatment of a patient with cancer is suddenly accelerated. To date, no reliable marker has been found to predict accelerated tumor growth during immune checkpoint inhibitor (ICI) treatment. The aim the present study was to summarize the definition of hyperprogression and the difference between hyperprogression and pseudocytosis, and investigate the potential mechanisms of hyperprogression including clinical characteristics, potential molecular markers and the immune microenvironment. The effect of macrophage-related different types and factors on tumors in the immune microenvironment was analyzed, and the findings may be used to determine the future directions of research in hyperprogression.

Identifiants

pubmed: 38223402
doi: 10.3892/mco.2023.2701
pii: MCO-20-1-02701
pmc: PMC10784782
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

3

Informations de copyright

Copyright © 2023, Spandidos Publications.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Auteurs

Ruizhe Qi (R)

Department of Pharmacy, The Second Affiliated Hospital of Xingtai Medical College, Xingtai, Hebei 054000, P.R. China.

Lihui Yang (L)

Department of Nursing, The Second Affiliated Hospital of Xingtai Medical College, Xingtai, Hebei 054000, P.R. China.

Xinchao Zhao (X)

Department of Pharmacy, The Second Affiliated Hospital of Xingtai Medical College, Xingtai, Hebei 054000, P.R. China.

Liying Huo (L)

Department of Pharmacy, The Second Affiliated Hospital of Xingtai Medical College, Xingtai, Hebei 054000, P.R. China.

Yaling Wang (Y)

Department of Pharmacy, Zhengzhou Ninth People's Hospital, Zhengzhou, Henan 450000, P.R. China.

Peifang Zhang (P)

Department of Nursing, The Second Affiliated Hospital of Xingtai Medical College, Xingtai, Hebei 054000, P.R. China.

Xiaomei Chen (X)

Department of Pharmacy, Baoan Central Hospital of Shenzhen, Shenzhen, Guangdong 518102, P.R. China.

Classifications MeSH